Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Trading 09-01 10:18:32 EDT

5.11

-0.09

-1.83%

High5.19	Low5.06	Vol146.08K
Open5.13	D1 Closing5.20	Amplitude2.50%
Mkt Cap142.20M	Tradable Cap138.99M	Total Shares27.86M
T/O746.78K	T/O Rate0.54%	Tradable Shares27.23M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":5.105,"timestamp":1788272310473,"preClose":5.2,"halted":0,"volume":146078,"delay":0,"changeRate":-0.01826923076923072,"floatShares":27225798,"shares":27855300,"eps":-1.558501,"marketStatus":"Trading","change":-0.095,"latestTime":"09-01 10:18:32 EDT","open":5.13,"high":5.19,"low":5.06,"amount":746776.5041592,"amplitude":0.025,"askPrice":5.11,"askSize":526,"bidPrice":5.1,"bidSize":901,"shortable":3,"etf":0,"ttmEps":-1.558501,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":5.2,"preHourTrading":{"tag":"盘前","latestPrice":5.16,"preClose":5.2,"latestTime":"09:02 EDT","volume":10205,"amount":52928.0049285,"timestamp":1788267746865,"change":-0.04,"changeRate":-0.007692,"amplitude":0.075},"postHourTrading":{"tag":"盘后","latestPrice":5.22,"preClose":5.2,"latestTime":"19:30 EDT","volume":25272,"amount":132181.9905,"timestamp":1788219002737,"change":0.02,"changeRate":0.003846,"amplitude":0.009231},"volumeRatio":2.020822,"impliedVol":0.8091,"impliedVolPercentile":0.2718},"requestUrl":"/m/hq/s/UNCY/tweets","defaultTab":"tweets","newsList":[{"id":"2664855885","title":"Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855885","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855885?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:05","pubTimestamp":1788260700,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “C","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353981/0/en/unicycive-therapeutics-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UNCY","ODD","IE0009354923.USD","BK4183","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660282383","title":"Unicycive Therapeutics price target raised to $15 from $13 at Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2660282383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660282383?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:40","pubTimestamp":1787229649,"startTime":"0","endTime":"0","summary":"Benchmark analyst Bruce Jackson raised the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $13 and keeps a Speculative Buy rating ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-raised-to-15-from-13-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-raised-to-15-from-13-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660811404","title":"U.S. Research Roundup-Amgen, Analog Devices, Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2660811404","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660811404?lang=en_us&edition=fundamental","pubTime":"2026-08-20 15:47","pubTimestamp":1787212055,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amgen, Analog Devices, ModernaAug 20 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amgen, Analog D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL4N44H0HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PJP","MRVL","PCTY","AMGN","UNCY","ARTY","WOLF","LWAY","NIQ","TJX","WDAY","RLAY","MRK","TGT","BILL","IBBQ","AIPI","EL","APA","KIDS","ADSK","MRNA","PGR","GKOS","KBWP","ALIT","XLV","IHE","TRUH","CING","ADI","ALL","RARE","WHD","LOW","HCA","ABBV","LNSR","XNTK","NRGV","SMHX","EPR","WISE","MSGE","SNOW","SPHR","CRWD","IHF","FRNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660148835","title":"Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2660148835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660148835?lang=en_us&edition=fundamental","pubTime":"2026-08-17 15:39","pubTimestamp":1786952395,"startTime":"0","endTime":"0","summary":"B. Riley lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $20 from $22 and keeps a Buy rating on the shares. The Q2 update was c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-20-from-22-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-20-from-22-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660007106","title":"Unicycive Therapeutics Posts Corporate Presentation on Kidney Disease Drug Pipeline, Led by OLC for Dialysis Hyperphosphatemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2660007106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660007106?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:58","pubTimestamp":1786931915,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemiaUnicycive outlined plans to resubmit its NDA for oxylanthanum carbonate, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLbkxRdV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659314152","title":"Clene Q2 Net Loss Widens on Higher Other Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659314152","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659314152?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:40","pubTimestamp":1786711241,"startTime":"0","endTime":"0","summary":"Clene Q2 net loss widens on higher other expensesOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr, driven by higher other expensesCompany closed $7 mln stock offering and extended debt ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0FV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","UNCY","BK4539","AEON","CLNN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162006","title":"Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162006","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162006?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652214,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Q2 net loss widens on warrant liability changesOverviewUS biotech reported Q2 net loss widened yr/yr, driven by non-cash warrant liability changesOperating expenses for Q2 fell ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A158:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACHV","BK4539","ELDN","BK4139","UNCY","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659316818","title":"Unicycive Therapeutics Price Target Cut to $20.00/Share from $22.00 by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2659316818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659316818?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:05","pubTimestamp":1786629900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659501581","title":"B. Riley Securities Reaffirms Their Buy Rating on Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659501581","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659501581?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:36","pubTimestamp":1786628208,"startTime":"0","endTime":"0","summary":"B. Riley Securities analyst Mayank Mamtani maintained a Buy rating on Unicycive Therapeutics today and set a price target of $20.00. According to T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/b-riley-securities-reaffirms-their-buy-rating-on-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/b-riley-securities-reaffirms-their-buy-rating-on-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154446","title":"B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154446","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154446?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:21","pubTimestamp":1786623702,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) has an average rating of buy and mean price target of $31.30, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659180317","title":"Unicycive Therapeutics Inc : Guggenheim Cuts Target Price to $25 from $37","url":"https://stock-news.laohu8.com/highlight/detail?id=2659180317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659180317?lang=en_us&edition=fundamental","pubTime":"2026-08-13 11:45","pubTimestamp":1786592752,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN4491NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900699","title":"Inovio Q2 Net Loss Narrows on Warrant Gain, Lower Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900699","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900699?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:14","pubTimestamp":1786565676,"startTime":"0","endTime":"0","summary":"Inovio Q2 net loss narrows on warrant gain, lower costsOverviewUS biotech firm's Q2 net loss narrowed yr/yr, driven by non-cash warrant gainQ2 operating expenses fell due to lower compensation and dev","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N449116:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4583","UNCY","GANX","BK4139","BK4539","INO","TOVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659909429","title":"Unicycive Rises on Narrower Quarterly Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2659909429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659909429?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:12","pubTimestamp":1786551150,"startTime":"0","endTime":"0","summary":"BUZZ-Unicycive rises on narrower quarterly loss** Shares of drug developer Unicycive TherapeuticsUNCY.Orise 9.2% to $5.46** Co posted Q2 net loss of $1.7 million, compared to a net loss of $6.5 millio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N4491DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908540","title":"Unicycive Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908540","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908540?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:31","pubTimestamp":1786541509,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryUnicycive Therapeutics IncUNCY.OQreported a quarterly adjusted loss of 52 cents per share for the quarter end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4491D0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974615","title":"Unicycive Therapeutics Q2 Net Loss Narrows on Warrant Liability Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974615","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974615?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:31","pubTimestamp":1786534264,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Q2 net loss narrows on warrant liability changeOverviewUS kidney disease biotech's Q2 net loss narrowed from prior yearNet loss decline attributed to change in fair value of war","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4539","PROK","BK4139","SCYX","ACHV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971054","title":"Unicycive Therapeutics Q2 EPS USD -0.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971054?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:20","pubTimestamp":1786533640,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXSW5DRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971778","title":"Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971778?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:19","pubTimestamp":1786533580,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA96DVLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UNCY","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658710919","title":"Unicycive Therapeutics - Q2 Net Loss was $1.70 Mln or $0.06 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2658710919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658710919?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:19","pubTimestamp":1786533580,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA96DVLX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658600979","title":"Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658600979","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658600979?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:43","pubTimestamp":1786531405,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.34) by 82.35 percent. This is a 88.46 percent increase over losses of $(0.52) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61136055/unicycive-therapeutics-q2-eps-0-06-beats-0-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658864979","title":"Unicycive Net Loss Widens 147% to USD 14.55 Million in FY26 First Half","url":"https://stock-news.laohu8.com/highlight/detail?id=2658864979","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658864979?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:32","pubTimestamp":1786530743,"startTime":"0","endTime":"0","summary":"Unicycive net loss widens 147% to USD 14.55 million in FY26 first halfUnicycive posted a GAAP net loss of USD 14.55 million for the six months ended June 30, 2026, widening 147%.Quarterly GAAP net los","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL58S5vH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":-0.0262},{"period":"1month","weight":0.0379},{"period":"3month","weight":-0.2808},{"period":"6month","weight":-0.2645},{"period":"1year","weight":0.2411},{"period":"ytd","weight":-0.0988}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0268},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1196},{"period":"1year","weight":0.1891},{"period":"ytd","weight":0.1248}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.078139},{"month":2,"riseRate":0.6,"avgChangeRate":0.088088},{"month":3,"riseRate":0.4,"avgChangeRate":0.59683},{"month":4,"riseRate":0.4,"avgChangeRate":-0.11937},{"month":5,"riseRate":0.4,"avgChangeRate":-0.060546},{"month":6,"riseRate":0,"avgChangeRate":-0.217882},{"month":7,"riseRate":0.2,"avgChangeRate":-0.068802},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.095849},{"month":9,"riseRate":0.6,"avgChangeRate":0.038818},{"month":10,"riseRate":0.8,"avgChangeRate":0.050976},{"month":11,"riseRate":0.6,"avgChangeRate":0.060673},{"month":12,"riseRate":0.4,"avgChangeRate":0.09852}],"exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction